Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profiling of [14C]-Dazucorilant in Healthy Men
NCT04990310Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dazucorilant in amyotrophic lateral sclerosis (ALS), sponsored by Corcept Therapeutics. Primary endpoint: Mass Balance Recovery in Excreta After a Single Dose of [14C]-CORT113176 up to 28 days. Started Aug 2021; status: completed.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04990310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990310.